ANO1 and head and neck squamous cell carcinoma: Taken together, the authors believe that a combination therapy using anti-TMEM16A and anti-PD-L1 inhibitors can be a promising strategy to improve the survival rate of HNSCC, particularly when the tumor gains resistance to anti-EGFR inhibitor treatment.